Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

. 2025 May ; 9 (5) : e70137. [epub] 20250503

Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection

Typ dokumentu dopisy

Perzistentní odkaz   https://www.medvik.cz/link/pmid40322296

Zobrazit více v PubMed

Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934‐1942. PubMed PMC

Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood. 2022;139(19):2871‐2881. 10.1182/blood.2022015680 PubMed DOI

Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534‐3544. PubMed PMC

Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550‐1559. PubMed

Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study. Lancet Haematol. Mar 2020;7(3):e196‐e208. 10.1016/S2352-3026(19)30236-4 PubMed DOI

Kiladjian J‐J, Klade C, Georgiev P, et al. Long‐term outcomes of polycythemia vera patients treated with ropeginterferon Alfa‐2b. Leukemia. 2022;36(5):1408‐1411. PubMed PMC

Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829‐4833. 10.1182/blood-2008-09-176818 PubMed DOI

Gisslinger H, Klade C, Georgiev P, et al. Event‐free survival in patients with polycythemia vera treated with ropeginterferon alfa‐2b versus best available treatment. Leukemia. Oct 2023;37(10):2129‐2132. 10.1038/s41375-023-02008-6 PubMed DOI PMC

Verger E, Soret‐Dulphy J, Maslah N, et al. Ropeginterferon alpha‐2b targets JAK2V617F‐positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8(10):94. PubMed PMC

Beauverd Y, Ianotto J‐C, Thaw KH, et al. Impact of cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and polycythemia vera. Blood. 2023;142:748.

Abu‐Zeinah G, Krichevsky S, Cruz T, et al. Interferon‐alpha for treating polycythemia vera yields improved myelofibrosis‐free and overall survival. Leukemia. 2021;35(9):2592‐2601. PubMed PMC

Guglielmelli P, Loscocco GG, Mannarelli C, et al. JAK2V617F variant allele frequency > 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11(12):199. PubMed PMC

Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574‐1579. PubMed

Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 2009;94(1):7‐10. PubMed PMC

Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011;2(1):21‐32. PubMed PMC

Najít záznam

Citační ukazatele

Možnosti archivace